Subcutaneous anifrolumab 120 mg weekly demonstrated a statistically significant and clinically meaningful reduction in SLE disease activity (58.5% BICLA response vs 43.2% for placebo) with a safety ...
Credit: AstraZeneca. The new weekly 120mg SC formulation, supported by TULIP-SC trial results, offers patients with moderate to severe SLE a self-administered alternative to monthly IV infusions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results